LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Home・Aandelen Lijst・Novartis AG

Novartis AG

Gesloten

145.93 0.38

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

145.76

Max

146.31

Belangrijke statistieken
By Trading Economics
Inkomsten	747M 3.2B
Verkoop	189M 14B
K/W Sectorgemiddelde	20.69 49.8
EPS	1.99
Dividendrendement	3.23
Winstmarge	23.336
Werknemers	75,267
EBITDA	338M 5.4B

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+16.58% upside

Dividenden
By Dow Jones
Dividendrendement Sectorgemiddelde	3.23% 2.25%

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-2.4B 276B
Vorige openingsprijs	145.55
Vorige sluitingsprijs	145.93

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

N/A / 112.63 Steun & Weerstand

Novartis AG Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

28 apr 2026, 09:05 UTC

Winsten

Novartis Earnings Hit by Generic Competition -- Update

28 apr 2026, 05:51 UTC

Winsten

Novartis Could Upgrade Future Growth Outlook

27 mrt 2026, 10:24 UTC

Acquisities, Fusies, Overnames

Novartis to Buy Allergy-Drug Developer Excellergy for Up to $2 Billion -- Update

27 mrt 2026, 06:36 UTC

Acquisities, Fusies, Overnames

Novartis to Buy Biotech Excellergy for Up to $2 Billion

28 apr 2026, 09:18 UTC

Marktinformatie

Winsten

European Pharma Stocks Slip After Novartis Books Sales, Profit Drop -- Market Talk

28 apr 2026, 07:26 UTC

Marktinformatie

Winsten

Novartis's Results Are Mixed -- Market Talk

28 apr 2026, 05:07 UTC

Winsten

Novartis: Multiple Drug Readouts in 2H Could Raise Mid- to Long-Term Growth Outlook

28 apr 2026, 05:05 UTC

Winsten

Novartis: On Track to Deliver Full-Year Guiance

28 apr 2026, 05:04 UTC

Winsten

Novartis Sees 2026 Core Operating Income Declining by Low Single-digit

28 apr 2026, 05:04 UTC

Winsten

Novartis Sees 2026 Net Sales Growing by Low Single-digit

28 apr 2026, 05:03 UTC

Winsten

Novartis 1Q Core EPS $1.99

28 apr 2026, 05:03 UTC

Winsten

Analysts Saw Novartis 1Q Core Operating Profit at $5.1B

28 apr 2026, 05:02 UTC

Winsten

Novartis 1Q Core Operating Profit $4.90B

28 apr 2026, 05:02 UTC

Winsten

Analysts Saw Novartis 1Q Sales at $13.34B

28 apr 2026, 05:01 UTC

Winsten

Novartis 1Q Sales $13.11B

28 apr 2026, 05:00 UTC

Winsten

Novartis Backs 2026 View

28 apr 2026, 05:00 UTC

Winsten

Novartis AG 1Q EPS $1.65

28 apr 2026, 05:00 UTC

Winsten

Novartis AG 1Q Net Pft $3.2B

28 apr 2026, 05:00 UTC

Winsten

Novartis AG 1Q Adj EPS $1.99

24 apr 2026, 05:20 UTC

Winsten

Novartis Is Making Coartem Available on Largely Not-For-Profit Basis in Malaria-Endemic Regions

24 apr 2026, 05:19 UTC

Winsten

Novartis: Process Is to Assess Quality, Safety and Efficacy of Treatments

24 apr 2026, 05:19 UTC

Winsten

Novartis: Prequalification Is a Process Run by the WHO

10 apr 2026, 11:45 UTC

Marktinformatie

Novartis Investors to Focus on Pipeline Update Amid Weak Results -- Market Talk

2 apr 2026, 08:01 UTC

Marktinformatie

Novartis Likely to Confirm Guidance -- Market Talk

30 mrt 2026, 09:37 UTC

Marktinformatie

Novartis to Take Earnings Hit From Generic Competition -- Market Talk

27 mrt 2026, 07:54 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Novartis's Excellergy Payments Should Be Back-End Loaded -- Market Talk

27 mrt 2026, 06:22 UTC

Acquisities, Fusies, Overnames

Correct: Novartis Will Pay Up to $2B Upfront, and Milestone Payments

27 mrt 2026, 06:05 UTC

Acquisities, Fusies, Overnames

Novartis: Transaction Is Expected to Close in 2H 2026, Subject to Approvals

27 mrt 2026, 06:04 UTC

Acquisities, Fusies, Overnames

Novartis Will Pay Up to $2B Upfront Followed by Milestone Payments

27 mrt 2026, 06:03 UTC

Acquisities, Fusies, Overnames

Novartis: Exl-111 Is a Half-Life Extended, High-Affinity anti-IgE Antibody in Phase 1

Peer Vergelijking

Prijswijziging

Novartis AG Prognose

Koersdoel

By TipRanks

16.58% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 170.24 USD 16.58%

Hoogste 180.191 USD

Laagste 141 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Novartis AG - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

Buy

Hold

Sell

Gebaseerd op 6 analisten die aandelenratings hebben gegeven aan Novartis AG - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

N/A / 112.63Steun & Weerstand

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.